NovaBridge Biosciences

NovaBridge Biosciences rose approximately 5.0% to $2.090 during regular trading, driven by positive market reception to the appointment of a new CEO. The company announced the appointment of Srishti Gupta as CEO, replacing Sean Fu, with the management change breaking the stock out of its recent consolidation range. Opening at $2.010, shares steadily climbed to an intraday high of $2.090, while the intraday low of $2.000 was recorded in pre-market trading. On a price-position basis, the stock remains 69.22% below its 52-week high of $6.79 but has recovered 43.15% from its 52-week low of $1.46, trading above both its MA20 ($1.656) and MA60 ($2.012). Financially, the company remains unprofitable, with Q4 2025 net loss widening to $72.858 million and EPS of -$0.6305, though its pipeline asset givastomig has secured FDA support for an accelerated approval pathway in gastric cancer.